Introduction {#s1}
============

The incidence of breast cancer is the first in female malignant tumors, in which the highest incidence of breast cancer has been reported in Europe and the United States, however, in recent years, the incidence of breast cancer in China has annually increased ([@B1], [@B2]). Based on surgery as an important step in the treatment of breast cancer, in recent years, different individuals have never stopped exploration of a novel and optimum approach. Besides, NSABP-04, ASCOG-Z0011, and other tests have shown that for breast cancer patients with T1-T2 stage and clinical negative lymph node (cN0) during breast preservation surgery and total breast radiotherapy, axillary lymph node dissection (ALND) does not contain great benefits to the long-term survival of patients. As a result, sentinel lymph node biopsy (SLNB) has been gradually replaced with conventional ALND as a routine surgical method for early breast cancer patients ([@B3]--[@B7]). However, SLNB, as an invasive operation, leads to some postoperative complications. Although the corresponding incidence rate is lower than ALND, however, those complications should not be ignored. Moreover, SLNB has a high degree of professional requirement for physicians, and the richness of physician\'s experience directly affects the evaluation of the pathological status of sentinel lymph nodes (SLN).

In recent years, the concepts of precision medicine and individualized therapy have rapidly developed. We often ask the following questions: "Can SLNB be omitted for patients with lower probability of sentinel lymph node metastasis?" "OR For patients with higher probability of sentinel lymph node metastasis, can the SLNB to be skipped and the armpit treatment to be directly conducted?" OR "For patients with neoadjuvant chemotherapy, should we have an SLNB before neoadjuvant chemotherapy, or after it?" The state of axillary lymph nodes is not only a key factor in determining the mode of surgery, but also an important prognostic factor, and before surgery, patients often would like to know whether there is a transfer of SLN. With the idea of micro-non-invasive operation, several scholars have developed and used mathematical models to predict the pathological state of SLN before operation, in which the most important predictive model was designed in 2007 at Memorial Sloan-Caitlin Cancer Center (MSKCC; NY, USA). It has been shown that with a receiver operating characteristic (ROC) curve of 0.75, a proper level of prediction and discrimination can be achieved ([@B8]--[@B24]). However, there are differences in the sources of patients (ethnic, regional, cultural, economic conditions, disease awareness, etc.), surgical methods, pathological evaluation methods, and other factors. Hence, it is difficult to have a predictive model that can be universally used. The clinical and pathological parameters for the application of different predictive models are not the same. Hence, the purpose of our study was to analyze the clinical and pathological data of early breast cancer patients in a more comprehensive way, and establish a predictive model for sentinel lymph node pathology. Technically, nomogram which is now used worldwide use multiple logistic regression (MLR) to predict a binary outcome based on a combination of risk factors. This well-established method has a limitation in that it incorporates only a few independent variables so that the model can accurately predict risk in independent datasets, by avoiding over-fitting to the given datasets. Such prediction models should also tolerate missing values, which are common in clinical datasets ([@B15]). Thus, we use SMOTE-Bagged Tree as a core algorithm to cope with a greater number of variables and that provide accurate prediction and robustness against missing values. In addition to the variables analyzed by other scholars, we added some specific variables, such as breast glandular content, molybdenum target tumor morphology, and primary location of the tumor (clock direction and distance from the nipple). Our study for the first time presents a model to analyze these factors as well.

Materials and Methods {#s2}
=====================

Patients
--------

In this study, 633 patients with a clear state through sentinel lymph node examination (including lymph node biopsy and surgical treatment with ALND) were included. Analysis of clinical data involves the following variables: age, body mass index (BMI), tumor size, tumor location (quadrant, clock direction, distance from the nipple), clinical staging, pathological type, pathological classification, immunohistochemistry (IHC) \[Estrogen receptor (ER), Progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), (Ki-67)\], grading of tumor tissue, menopausal state, molybdenum target glandular content, and morphology and sentinel lymph node metastasis of molybdenum. The patient\'s information was derived from the Shengjing Hospital of China Medical University (Shenyang, China) during January 2011 to December 2014. The patients with early-stage breast cancer who met the following criteria were selected for treatment with SLNB: (1) diagnosis of breast cancer; (2) without receiving neoadjuvant chemotherapy; (3) the result for preoperative axillary lymph node to be negative, according to clinical and imaging examinations; (4) Primary diameter of tumor ranges at 0--5 cm; (5) Complete clinicopathological information; and (6) without pregnancy. Patients with incomplete data, metastasis of 3 and above axillary lymph nodes, distant metastasis, preoperative neoadjuvant chemotherapy, and radiotherapy were excluded. All patients involved in the present study signed a written informed consent form prior to their inclusion in the study. The study was approved by the Ethics Committee of Shengjing Hospital of China Medical University.

Surgery Procedure
-----------------

A standard breast cancer surgery was conducted on the basis of guidelines for the treatment of breast cancer patients in China. Surgery included primary tumor resection and lymph node biopsy (or ALND). The number and pathological status of SLN were detected after operation as well.

Pathologic Evaluation
---------------------

The Chinese breast cancer guidelines were used to evaluate surgical specimens. Tumors with \> 10% nuclear-stained cells were considered positive for ER and PR. Ki67 expression \> 20% was also considered positive. The HER-2 positivity was defined as a score of 3+ on IHC or amplification on FISH. If a pathologist scored the IHC 2+, the status of HER-2 was further investigated by FISH. In addition, the grade of breast cancer was determined by the Nottingham Histologic Scoring system. Tumor staging refers to the TNM staging method jointly conducted and published in form of the 8th edition by the International Anticancer Alliance (UICC) and the American Oncology Federation (AJCC) in 2018. The SLNs were step sectioned, stained with hematoxylin and eosin (H&E), and diagnosed by trained pathologists. Lymph nodes obtained after ALND were evaluated using a single H&E stained section from each node. Metastases were defined as the presence of a tumor deposit \>0.2 mm in diameter in at least one lymph node.

Location of the Tumor
---------------------

We use the polar coordinates to paint. We counted the location of the tumor in the direction of the clock and the distance from the nipple (the factor of the clock in the left and right sides of the breast has been taken into account). The number of cases transferred at the same location is proportional to the radius, and then the nipple is the center of the circle, in which the distance is the radius of the mapping ([Figure 1](#F1){ref-type="fig"}).

![Vector diagram of the location of the tumor in breast. We counted the location of the tumor in the direction of the clock and the distance from the nipple (the factor of the clock in the left and right sides of the breast has been taken into account). The number of cases transferred at the same location is proportional to the radius, and then the nipple is the center of the circle, in which the distance is the radius of the mapping.](fonc-09-00282-g0001){#F1}

Statistical Analysis
--------------------

In this study, MATLAB2018a was used for data processing, and statistical analysis was undertaken by using SPSS 25.0 statistical software (SPSS Inc., Chicago, IL, USA) and R software. The statistical significance level of the report was double-sided, and it was set to 0.05.

Smote Algorithm Generates Data
------------------------------

There are a number of methods available to oversample a dataset used in a typical classification problem (using a classification algorithm to classify a set of images, given a labeled training set of images). The most common technique is known as SMOTE: Synthetic Minority Over-sampling Technique ([@B25]).

According to the natural occurrence of disease, breast cancer grows more in the outer upper quadrant. However, in the process of regular grouping, such case characteristic data is unbalanced (the proportion of the outer upper quadrant tumor is larger), which will affect the broad applicability of the model, so it is not appropriate to use the classifier to distinguish directly. Therefore, this study used the most appropriate smote algorithm to upsample the data to increase the balanced amount of data, reconstruct the training set, and obtain a relatively balanced training set.

The basic idea of smote algorithm is to analyze a few kinds of samples and add them to the dataset according to a few samples of synthetic samples, and the algorithm flow is as follows. (1) For each sample x in a few classes, the Euclidean distance is used as the criterion for calculating the distance of all samples in a few sample sets, and its k neighbor is obtained. (2) Set a sampling scale according to the unbalanced proportion of the sample to determine the sampling magnification n, for each minority sample X, from its K near neighbor randomly selected a number of samples, assuming that the selected neighbor is xn. (3) For each randomly selected near neighbor Xn, a new sample is constructed with the original sample according to the following formula.
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Confusion Matrix
----------------

Confusion matrix is an important tool to evaluate the performance of classification model. A variety of evaluation indexes, such as true positive rate, false positive rate, true negative rate, false negative rate and accuracy, can be calculated by the obfuscation matrix. In particular, the confusion matrix distinguishes between false positives and false negatives of two different properties of miscalculation, which can be used to estimate the expected loss caused by miscalculation of the classification model. When the classification model returns the probability or score of each record belonging to the positive category, a obfuscation matrix can be obtained by specifying the threshold and making a positive judgment on all the probabilities or records that are rated above the threshold. By continuously changing the threshold value, different obfuscation matrices can be obtained, so that the ROC curve, and the performance of the classification model is evaluated and compared more comprehensively.

Establishment of Predictive Models
----------------------------------

First, we use the logistic regression method which was commonly used in other research centers to build prediction models, and then use the Bagged Tree algorithm to build prediction models. In the end we compared the results obtained by the two methods. The amplified data were classified using the Bagged Tree algorithm. It was used to analyze the following clinical candidate predictors: age, BMI, quadrant, clock direction, the distance of tumor from the nipple, morphology of tumor molybdenum target, glandular content, tumor size, ER, PR, HER2, and Ki-67. The trees in Bagged Trees were built on their own sampled datasets, and the training process was independent. The Bagged Tree algorithm extracts multiple random datasets to fit multiple decision tree models in order to improve model\'s performance. Each decision tree differs because of the subset data, and the final prediction results are determined based on the prediction of all trees ([@B26]). Accordingly, the versatility of predictions increases. The ROC curve was plotted, and the area under the curve (AUC) was here used to estimate the prediction accuracy of the model.

Results {#s3}
=======

Patient Characteristics
-----------------------

Our study included 633 patients who underwent sentinel lymph node examination, in which 35.8% of whom had sentinel lymph node metastasis. The descriptive characteristics of the model population are presented in [Table 1](#T1){ref-type="table"}. In fact, the characteristic data of lymph node metastasis in breast cancer were not balanced, and utilizing a classifier to directly distinguish was not appropriate. Therefore, the SMOTE was used to sample the breast cancer dataset and reduce the imbalance of the training set. An oversampling algorithm was also used to add new information to the unbalanced data. In our study, 633 cases of raw data were sampled by SMOTE, in which 169 new data were generated according to the characteristics of the original data. We analyzed the newly generated data and raw data (a total of 802 cases) together.

###### 

Comparison of descriptive characteristics of the SLN+ group and SLN- group for the model.

  **Variable**              **N**   **SLN+**   **SLN-**   ***P*-value**            
  ------------------------- ------- ---------- ---------- --------------- -------- -------
  No. of cases              633     227        35.86      406             64.14    
  Age                                                                              0.536
  \<40                      52      17         32.69      35              67.31    
  40--70                    547     195        35.65      352             64.35    
  \>70                      34      15         44.12      19              55.88    
  AJCC T stage                                                                     0.149
  T1a                       1       0          0.00       1               100.00   
  T1b                       7       0          0.00       7               100.00   
  T1c                       349     118        33.81      231             66.19    
  T2 \< 3.0 cm              262     103        39.31      159             60.69    
  T2 \> 3.0 cm              14      6          42.86      8               57.14    
  Left/Right breast                                                                0.511
  left                      318     127        39.94      191             60.06    
  right                     315     100        31.75      215             68.25    
  Neuroinvasion                                                                    0.102
  Present                   4       3          75.00      1               25.00    
  Absent                    629     224        35.61      405             64.39    
  Lymphovascular invasion                                                          0.232
  Present                   16      8          50.00      8               50.00    
  Absent                    617     219        35.49      398             64.51    
  Tumor location                                                                   0.441
  UOQ                       313     122        38.98      191             61.02    
  LOQ                       47      15         31.91      32              68.09    
  UIQ                       127     38         29.92      89              70.08    
  LIQ                       42      16         38.10      26              61.90    
  Central                   104     36         34.62      68              65.38    
  Tumor type                                                                       0.000
  Ductal                    609     211        34.65      398             65.35    
  Lobular                   10      4          40.00      6               60.00    
  Mixed                     10      10         100.00     0               0.00     
  Mucinous                  3       2          66.67      1               33.33    
  Medullary                 1       0          0.00       1               100.00   
  Clinical stage                                                                   0.000
  I                         191     3          1.57       188             98.43    
  II                        440     223        50.68      217             49.32    
  III                       2       1          50.00      1               50.00    
  Pathological grade                                                               0.063
  1                         17      4          23.53      13              76.47    
  2                         582     205        35.22      377             64.78    
  3                         34      18         52.94      16              47.06    
  ER                                                                               0.099
  Present                   481     181        37.63      300             62.37    
  Absent                    152     46         30.26      106             69.74    
  PR                                                                               0.164
  Present                   427     161        37.70      266             62.30    
  Absent                    206     66         32.04      140             67.96    
  HER2                                                                             0.534
  Present                   88      31         35.23      57              64.77    
  Absent                    545     196        35.96      349             64.04    
  Ki67                                                                             0.960
  Present                   392     148        37.76      244             62.24    
  Absent                    241     79         32.78      162             67.22    
  Breast gland content                                                             0.214
  \<25%                     99      31         31.31      68              68.69    
  26--50%                   184     42         22.83      142             77.17    
  51--75%                   305     113        37.05      192             62.95    
  \>75%                     45      11         24.44      34              75.56    
  Tumor morphology                                                                 0.366
  Lump                      378     130        34.39      248             65.61    
  Mass with calcification   96      41         42.71      55              57.29    
  No mass                   159     56         35.22      103             64.78    
  BMI                                                                              0.726
  Too light                 21      7          33.33      14              66.67    
  Normal                    313     108        34.50      205             65.50    
  Overweight                299     112        37.46      187             62.54    

Predictors of SLNM
------------------

In the multi-factor analysis, we included the following variables associated with breast cancer SLN metastasis: age, BMI, quadrant, clock direction, the distance of tumor from the nipple, morphology of tumor molybdenum target, glandular content, tumor size, ER, PR, HER2, and Ki-67 ([Figure 2](#F2){ref-type="fig"}).

![The ability of each variable to predict breast cancer SLN metastasis. Each point represents in turn: Age, body mass index(BMI), Quadrant, Clock direction, The distance of tumor from the nipple, Morphology of tumor molybdenum target, Glandular content, Tumor size, ER, PR, HER2,Ki-67, Vector (Clock direction and The distance of tumor from the nipple).](fonc-09-00282-g0002){#F2}

Construction and Validation of the Model by Logistic Regression
---------------------------------------------------------------

We are grateful for your advice. Our study included 633 patients randomized into a modeling set (*n* = 500) and a validation set (*n* = 133). The clinicopathological characteristics of the patients did not differ significantly between the two groups (*P* \> 0.05) in our study population ([Table 2](#T2){ref-type="table"}). The internal ROC curves in the modeling set and external ROC in the validation set were used to evaluate the model. In the modeling and validation groups, the AUC were 0.660 and 0.580 ([Figures 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}).

###### 

Comparison between modeling group and validation group by clinicopathological characteristics.

  **Variable**              ***N***   **Modeling**   **Validation**   ***P*-value**           
  ------------------------- --------- -------------- ---------------- --------------- ------- -------
  No. of cases              633       500                             133                     
  Age                                                                                         0.892
  \<40                      52        42             80.80            10              18.20   
  40--70                    547       432            79.00            115             21.00   
  \>70                      34        26             76.50            8               5.40    
  Tumor location                                                                              0.178
  UOQ                       313       241            77.00            72              23.00   
  LOQ                       47        42             89.40            5               10.60   
  UIQ                       127       96             75.60            31              24.40   
  LIQ                       42        36             85.70            6               4.30    
  Central                   104       85             81.70            19              18.30   
  Tumor type                                                                                  0.439
  Ductal                    609       483            79.3             126             20.70   
  Lobular                   10        6              60.00            4               40.00   
  Mixed                     10        7              70.00            3               30.00   
  Mucinous                  3         3              100.00           0               0.00    
  Medullary                 1         1              100.00           0               0.00    
  Clinical stage                                                                              0.270
  I                         191       157            82.20            34              17.80   
  II                        440       342            77.70            98              22.30   
  III                       2         1              50.00            1               50.00   
  Pathological grade                                                                          0.899
  1                         17        13             76.50            4               23.50   
  2                         582       461            79.20            161             20.80   
  3                         34        26             76.50            8               23.50   
  ER                                                                                          0.353
  Present                   481       384            79.80            97              20.20   
  Absent                    152       116            76.30            36              23.70   
  PR                                                                                          0.234
  Present                   427       343            80.30            84              19.70   
  Absent                    206       157            76.20            49              23.80   
  HER2                                                                                        0.802
  Present                   88        71             80.70            17              19.30   
  Absent                    545       427            78.80            115             21.20   
  Ki67                                                                                        0.960
  Present                   392       148            37.76            244             62.24   
  Absent                    241       79             32.78            162             67.22   
  Breast gland content                                                                        0.769
  \<25%                     99        82             82.80            17              17.20   
  26--50%                   184       144            78.30            40              21.70   
  51--75%                   305       238            78.00            67              22.00   
  \>75%                     45        36             80.00            9               20.00   
  Tumor morphology                                                                            0.056
  Lump                      378       311            82.33            67              17.70   
  Mass with calcification   96        70             72.90            26              27.10   
  No mass                   159       119            74.80            40              25.20   
  SLN                                                                                         0.073
  Present                   227       170            74.90            57              24.10   
  Absent                    406       330            81.30            76              18.70   

![Internal validation using a ROC curve. Established model by logistic regression. The AUC value is 0.660.](fonc-09-00282-g0003){#F3}

![External validation using a ROC curve. Established model by logistic regression. The AUC value is 0.580.](fonc-09-00282-g0004){#F4}

Construction and Validation of the Model by SMOTE-Bagged Tree Algorithm
-----------------------------------------------------------------------

A bagged tree was used to categorize samples. In order to obtain a reliable and stable model, a 5-fold cross-validation was used for verification. A Sentinel lymph node prediction program was established by SMOTE-bagged tree algorithm. Since the original location of the tumor was analyzed by the combination of vector and quadrant for the first time, we used the method of simply using quadrant or vector for comparison. Finally, our model obtained the AUC value of 0.801 ([Figure 5](#F5){ref-type="fig"}), while the vector group is 0.791 ([Figure 6](#F6){ref-type="fig"}) and the quadrant group is 0.701 ([Figure 7](#F7){ref-type="fig"}). We use the confusion matrix to evaluate the accuracy of the model. The accuracy of our model is 70.3% ([Figure 8A](#F8){ref-type="fig"}), compared to 70.3% for the vector group ([Figure 8B](#F8){ref-type="fig"}) and 63.6% for the quadrant group ([Figure 8C](#F8){ref-type="fig"}).The mentioned method provides an accurate and credible multi-variable prediction model.

![Validation using a ROC curve. Established model by Smote-Bagged-tree and used Vector combining quadrant method to analyze. The location of the tumor. The AUC value is 0. 801.](fonc-09-00282-g0005){#F5}

![Validation using a ROC curve. Established by Smote-Bagged-tree and used Simply using vector method to analyze the location of the tumor. The AUC value is 0.791.](fonc-09-00282-g0006){#F6}

![Validation using a ROC curve. Established by Smote-Bagged-tree and used Simply using quadrant method to analyze the location of the tumor. The AUC value is 0.701.](fonc-09-00282-g0007){#F7}

![Confusion matrix. **(A)** Vector combining quadrant method, the Accuracy is 70.3%. **(B)** Simply using vector method, the Accuracy is 70.3%. **(C)** Simply using quadrant method, the Accuracy is 63.6%.](fonc-09-00282-g0008){#F8}

The inclusion of imaging and pathological detection factors in an easy-to-use machine learning model facilitates the prediction of lymph node metastasis in patients before surgery. Because lymph node metastasis is similar in training set and validation set, a predictive model for breast cancer lymph node metastasis based on Bagged Tree algorithm is of great importance, and can be directly applied to verify dataset. The experimental results showed that the prediction model for lymph node metastasis on the basis of SMOTE-Bagged Tee algorithm can effectively improve the rate of data utilization and assist doctors predict sentinel lymph node metastasis in breast cancer patients.

In order to make it easier to use in clinical applications, we have created an app that patients can use it easily by a personal computer, laptop, or smart phone. The operation method is simple, only the user should input the patient\'s clinicopathological information into the app.

Discussion {#s4}
==========

The prediction results obtained with the help of a predictive model are more credible than simple clinical guesses. The development of each predictive model is accomplished through the clinicopathological data of different populations. In our model, in terms of tumor size, we chose T1-T2 staging patients, because for the study of exemption from SLNB, the need for early clinical staging of the patient group, thus the size of tumor needs to be strictly limited. For type of tumor, we focused on invasive ductal carcinoma, which accounts for only a small fraction of lobular cancer and mucous cancer. As invasive ductal carcinoma accounts for the vast majority, in order to avoid the formation of bias, the type of tumor was not taken into account in the inclusion of variables. Because chemotherapy can affect lymphatic vessels, SLNB has a high failure rate and a high false negative rate, hence, we ruled out patients with preoperative neoadjuvant chemotherapy. There were two variables for nerve infiltration and vascular thrombosis, and because the selected cases were early breast cancer patients, the number of cases in these two states was very limited. Moreover, these two variables could only be learned by breast cancer surgery, and the establishment of a preoperative prediction model was not practical, thus the variables of the model were not included.

In several studies, tumor size is the main predictor of sentinel lymph node metastasis ([@B9]--[@B14]). According to the results of statistical analysis, we also confirmed that the rate of positive SLN was lower in the group of patients with smaller tumors. This is also consistent with the results of NSABP-04, ASCOG-Z0011, IBCSG 23-01, and other tests. Axillary lymph node dissection (ALND) is not necessary for early breast cancer patients with 1 to 2 positive SLNs after undergoing lumpectomy, radiotherapy (RT), and systemic treatment ([@B3], [@B4], [@B27]--[@B29]).

We compare and analyze the predictive ability of smote-bagged tree algorithm modeling and Logistic regression method modeling, and the results suggest that the model established by smote-bagged tree algorithm is more predictive. The main reasons are the following: (a) Because of the imbalance of data, using the Bagged-Tree algorithm can reduce the impact of data imbalance. It performs well on the category imbalance data and improves the prediction accuracy. (b) Feature normalization or standardization is not required. Especially when the scale of the feature is completely different or when the binary feature and the continuous feature exist simultaneously, the effect is very good.

To our knowledge, this is the first model analyzing and studying the original location of the tumor by both vector and quadrant. We analyzed the previously established axillary lymph node prediction models ([@B8]--[@B15], [@B17]--[@B20]), and found that there were different views on the effects of the primary location of the tumor on sentinel lymph node metastasis. The MSKCC model concluded that the risk of axillary lymph node metastasis in the upper inner quadrant was less, while there was no statistically different chance of axillary lymph node metastasis between other quadrants ([@B11]). In 2012, the SCH model proposed by Chinese scholars mentioned that in terms of the location of the tumor, the order of axillary lymph node metastasis from high to low should be the central quadrant, the lower inner quadrant, the outer upper quadrant, the lower outer quadrant, and the upper inner quadrant ([@B20]). This study takes into account the breast as a three-dimensional (3D) structure, thus we first proposed the primary location of the tumor through both vector and quadrant location analysis. By comparing the three methods, the results prove that: We used the vector combining quadrant method to analyze the original location of the tumor, which is more precise than simply using vector or quadrant. The combination of the two methods, the primary location of the tumor will be more precisely positioned.

BMI was used as an important factor in previous researches ([@B11], [@B20], [@B30]). To our knowledge, breast composition includes fat and glands, and BMI does not indicate the size of breast glands in the overall proportion of the breast, thus our study for the first time presents the breast gland content as an independent factor for analysis.

Breast malignant tumor has its special form; for example, ultrasound is typically classified through the morphology, boundaries, activity, and other conditions of the tumor; molybdenum target will be classified according to the shape of the tumor and calcification ([@B31]). In retrospect, the morphology of the tumor was not analyzed as a factor in previous studies. Because the judgment of ultrasound is subjective, we use the tumor morphology under molybdenum target as a factor for statistical analysis. After deep learning of the image by computer, the picture of the breast molybdenum target image is automatically identified, and the shape of the tumor is scientifically grouped, and that is used as an important factor in the production of predictive software.

Looking back at the predictive models of other researches, the variables included in each model are different, and we believe that a predictive model should be simplified on the basis of ensuring accuracy, rather than only simply pursuing variables. Our predictive model contains 12 variables: age, BMI, quadrant, clock direction, the distance of tumor from the nipple, morphology of tumor molybdenum target, glandular content, tumor size, ER, PR, HER2, and Ki-67. Generally speaking, when the AUC value of a model is at the range of 0.7--0.8, the prediction ability of the model is superior. When the AUC value is at the range of 0.8--0.9, the prediction ability of the model is very good. Through the SMOTE-Bagged Tree algorithm, the AUC value obtained by our model is 0.80, which proves that our model has a proper prediction ability, and can be used for early breast cancer patients.

Our SLN prediction model appropriately predicts the risk of sentinel metastasis in patients. For patients with low risk of SLN metastasis, especially those who cannot tolerate SLNB surgery, or patients with high retention requirements for postoperative limb sensory function, no SLNB can be considered clinically to improve the patients\' quality of life. For patients with high risk of SLN metastasis, axillary treatment can be directly performed, such as ALND, axillary radiotherapy, etc., especially for elderly or patients with poor foundation status, that can greatly shorten the duration of operation time. For patients undergoing neoadjuvant chemotherapy, this model can be used to predict its SLN state before the new auxiliary chemotherapy, and our model does not include the patients after the new adjuvant radiotherapy, and does not apply to the prediction after the new adjuvant chemotherapy, limiting the prediction ability of the model.

In clinical work, more and more patients are eager to understand the pathological state of SLN before surgery. Predictive results obtained using objective predictive models are more believable than pure clinical guesses. According to the sentinel lymph node prediction model established by this research data, the overall prediction ability is very high, the result of the ROC Curve area is 0.801, which suggests that our prediction model has good predictive ability and strong stability, so we believe that the model can be generally applied to other groups of people. Compared with other models, we used the factors for the first time as follows: the location of the tumor was analyzed by vector combining quadrant method, the content of the breast glands, and the shape of the tumor, which caused that our model to be more sophisticated. Since the variables required by the model can be obtained by ultrasound, molybdenum target, hollow core needle biopsy, or open biopsy, the patient is able to learn the risk of SLN metastasis before the operation to predict the prognosis of the disease.

However, our predictive model contains some limitations. Firstly, in the next study, for the variant of tumor morphology under molybdenum target, we should incorporate more data, and continue to improve the depth of machine learning, so that it can be used to more detailed grouping of tumor morphology, and strive to further identify calcification patterns. Secondly, the breast is such a 3D structure, in which for finding the location of the tumor, we will then improve its grouping, and strive to complete the 3D positioning. In addition, this is a retrospective and single-center study, and out model has a proper diagnostic ability, however, it needs to be further validated in other regions and populations.

Conclusions {#s5}
===========

In summary, we have established an accurate, reliable, and user-friendly multi-variable predictive model. By adding several variables that have never been used in previous models, our model can be used to predict the risk of sentinel lymph node metastasis before breast cancer surgery, and it provide a reliable basis for the treatment of axillary lymph nodes.
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SLN

:   Sentinel lymph node

SLNB

:   Sentinel lymph node biopsy

SLN+

:   Sentinel lymph node positive

SLN-

:   Sentinel lymph node negative

ALN

:   Axillary lymph node

ALND

:   Axillary lymph node dissection

MLR

:   Multiple logistic regression

SMOTE

:   Synthetic minority oversampling

UIQ

:   Upper inner quadrant

UOQ

:   Upper outer quadrant

LOQ

:   Lower outer quadrant

LIQ

:   Lower inner quadrant

Central

:   Central quadrant

ROC

:   Receiver operating characteristics curve

AUC

:   Area under the receiver operating characteristics curve

BMI

:   Body mass index

IHC

:   Immunohistochemistry

ER

:   Estrogen receptor

PR

:   Progesterone receptor

HER2

:   Human epidermal growth factor receptor 2.
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